tbuckley/cabot-search huggingface dataset:
L’apprentissage de la dissection sous-muqueuse endoscopique (ESD) vidéo-assistée
Journal: Endoscopy (2016)

L’apprentissage de la dissection sous-muqueuse (DSM) en Occident est difficile, d’une part car la technique est complexe avec une courbe d’apprentissage longue, d’autre part du fait du faible nombre d’experts disponibles dans chaque pays. Aussi, les endoscopistes se forment seuls, sur modèle porcin. Un programme d’apprentissage vidéo-assisté pourrait être une solution pour pallier ce manque.
Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus Infection
Authors: Edgar Bautista, Tawee Chotpitayasunondh, Zhancheng Gao, Scott A Harper, Michael Shaw, Timothy M Uyeki, Sherif R Zaki, Frederick G Hayden, David S Hui, Joel D Kettner, Anand Kumar, Matthew Lim, Nahoko Shindo, Charles Penn, Karl G Nicholson
Journal: New England Journal of Medicine (2010)
Response to: ‘Denosumab, cortical bone and bone erosion in rheumatoid arthritis’ by Rossini<i>et al</i>
Authors: Tsutomu Takeuchi, Yoshiya Tanaka, Naoki Ishiguro, Hisashi Yamanaka, Toshiyuki Yoneda, Takeshi Ohira, Naoki Okubo, Harry K Genant, Désirée van der Heijde
Journal: Annals of the Rheumatic Diseases (2016)

Dear Editor,

We thank Rossini et al for their comments1 on our recent study on inhibitory effect by denosumab on the progression of bone erosions in Japanese patients with rheumatoid arthritis (RA).2 They addressed their observation from point of view of bone in patient with RA. …
Predictors of margin status after breast-conserving operations for breast cancer.
Authors: I. K. Komenaka, R. Torabi, C. Hsu, M. E. Bouton
Journal: Journal of Clinical Oncology (2010)

e11078 Background: Breast-conserving operations are the recommended surgical operation for early-stage breast cancers. Along with radiation, negative margins are the most important factor in preventing local recurrence after a lumpectomy. The current study was performed to evaluate patient demographic, clinical, and treatment variables that may predict risk for positive margins. Methods: A retrospective chart review was performed of all patients who underwent breast-conserving operations from 2002-2009. Demographic, clinical, and treatment variables were compared in patients who had negative margins to those who had positive margins. A minimum of one millimeter from tumor to ink was considered a negative margin. Significant variables on univariate analysis were then included in an adjusted model to determine which remained significant in multivariate analysis. Results: Over the time period evaluated, 61 patients had positive margins (32%) and 130 had negative margins. Compared to patients with negative margins, patients with positive margins had a lower BMI and were less likely to have undergone a screening mammogram (p = 0.05). Clinical variables which predicted increased risk for positive margins included presentation with a palpable mass, not undergoing preoperative chemotherapy, and lymphovascular invasion (LVI), p = 0.05. In addition type of surgeon significantly affected margin status (p < 0.01). In multivariate analysis, presentation with a palpable mass, LVI, and surgeon remained significant predictors of margins status (p < 0.02). Having undergone preoperative chemotherapy was of borderline significance in avoiding positive margins (p = 0.06). Conclusions: At the institution studied, presentation with a palpable mass, LVI, and type of surgeon predicted increased risk of positive margins. In addition, having undergone preoperative chemotherapy was of borderline significance in avoiding positive margins. No significant financial relationships to disclose.
Cancer network activity associated with therapeutic response and synergism
Authors: Jordi Serra-Musach, Francesca Mateo, Eva Capdevila-Busquets, Gorka Ruiz de Garibay, Xiaohu Zhang, Raj Guha, Craig J. Thomas, Judit Grueso, Alberto Villanueva, Samira Jaeger, Holger Heyn, Miguel Vizoso, Hector Pérez, Alex Cordero, Eva Gonzalez-Suarez, Manel Esteller, Gema Moreno-Bueno, Andreas Tjärnberg, Conxi Lázaro, Violeta Serra, Joaquín Arribas, Mikael Benson, Mika Gustafsson, Marc Ferrer, Patrick Aloy, Miquel Àngel Pujana
Journal: Genome Medicine (2016)

Cancer patients often show no or only modest benefit from a given therapy. This major problem in oncology is generally attributed to the lack of specific predictive biomarkers, yet a global measure of cancer cell activity may support a comprehensive mechanistic understanding of therapy efficacy. We reasoned that network analysis of omic data could help to achieve this goal. A measure of "cancer network activity" (CNA) was implemented based on a previously defined network feature of communicability. The network nodes and edges corresponded to human proteins and experimentally identified interactions, respectively. The edges were weighted proportionally to the expression of the genes encoding for the corresponding proteins and relative to the number of direct interactors. The gene expression data corresponded to the basal conditions of 595 human cancer cell lines. Therapeutic responses corresponded to the impairment of cell viability measured by the half maximal inhibitory concentration (IC50) of 130 drugs approved or under clinical development. Gene ontology, signaling pathway, and transcription factor-binding annotations were taken from public repositories. Predicted synergies were assessed by determining the viability of four breast cancer cell lines and by applying two different analytical methods. The effects of drug classes were associated with CNAs formed by different cell lines. CNAs also differentiate target families and effector pathways. Proteins that occupy a central position in the network largely contribute to CNA. Known key cancer-associated biological processes, signaling pathways, and master regulators also contribute to CNA. Moreover, the major cancer drivers frequently mediate CNA and therapeutic differences. Cell-based assays centered on these differences and using uncorrelated drug effects reveals novel synergistic combinations for the treatment of breast cancer dependent on PI3K-mTOR signaling. Cancer therapeutic responses can be predicted on the basis of a systems-level analysis of molecular interactions and gene expression. Fundamental cancer processes, pathways, and drivers contribute to this feature, which can also be exploited to predict precise synergistic drug combinations.
PHB‐Based Gels as Delivery Agents of Chemotherapeutics for the Effective Shrinkage of Tumors
Authors: Yun‐Long Wu, Han Wang, Ying‐Kun Qiu, Sing Shy Liow, Zibiao Li, Xian Jun Loh
Journal: Advanced Healthcare Materials (2016)

Injectable thermogel to deliver chemotherapeutics in a minimally invasive manner and to achieve their long term sustained release at tumor sites to minimize side effects is attractive for chemotherapy and precision medicine, but its rational design remains a challenge. In this work, a copolymer with natural biodegradable poly[(R)‐3‐hydroxybutyrate] (PHB), hydrophilic poly(ethylene glycol), and temperature sensitive poly(propylene glycol) blocks linked by urethane linkages is designed to show thermogelling characteristics which are beneficial for minimally invasive injection and safe degradation. This thermogelling polymer possesses in vitro biocompatibility with very low cyto‐toxicity in HEK293 cells. Furthermore, it is able to form the gel to achieve the controllable release of paclitaxel (PTX) and doxorubicin (DOX) by adjusting polymer concentrations. A rodent model of hepatocarcinoma has been performed to demonstrate the in vivo applications of this PHB‐based thermogel. The drug‐loaded thermogel has been intratumorally injected and both PTX‐loaded and DOX‐loaded thermogel have significantly slowed down tumor growth. This work represents the first time that injectable PHB thermogels have possessed good controllable release effect of chemotherapeutics against the in vivo model of tumors and will benefit various applications, including on‐demand drug delivery and personalized medicine.
Donor Lymphocyte Infusion Vs. Second Allogeneic HCT In Relapsed AML After Allografting: A Landmark Analysis From The Acute Leukemia Working Party Of EBMT
Authors: Mohamed A Kharfan-Dabaja, Myriam Labopin, Taiga Nishihori, Ali Bazarbachi, Jürgen Finke, Gerhard Ehninger, Matthias Stelljes, Nicolaus Kroeger, Bruno Lioure, Arnon Nagler, Lothar Kanz, Johanna Tischer, Ernst Holler, Christoph Schmid, Mohamad Mohty
Journal: Blood (2013)
Case 24-1988
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, Sidney S. Braman, Eugene J. Mark
Journal: New England Journal of Medicine (1988)

Presentation of CaseA 32-year-old woman was admitted to the hospital because of recurrent right pneumothorax.She was well until 32 months earlier, when a spontaneous right pneumothorax developed; a chest tube was inserted, and she recovered in 10 days. Five months later another right pneumothorax, 80 to 90 percent, was again treated by insertion of a chest tube. Twenty months before entry a recurrence of right pneumothorax was again managed with a chest tube, and tetracycline sclerosis was performed twice. Three months before admission a fourth episode of right pneumothorax occurred, and she came to this hospital. An x-ray . . .
<i>In vivo </i>Biocompatibility, Biodistribution and Therapeutic Efficiency of Titania Coated Upconversion Nanoparticles for Photodynamic Therapy of Solid Oral Cancers
Authors: Sasidharan Swarnalatha Lucky, Niagara Muhammad Idris, Kai Huang, Jaejung Kim, Zhengquan Li, Patricia Soo Ping Thong, Rong Xu, Khee Chee Soo, Yong Zhang
Journal: Theranostics (2016)

Despite the advantages of using photodynamic therapy (PDT) for the treatment of head and neck tumors, it can only be used to treat early stage flat lesions due to the limited tissue penetration ability of the visible light. Here, we developed near-infrared (NIR) excitable upconversion nanoparticle (UCN) based PDT agent that can specifically target epithelial growth factor receptor (EGFR) overexpressing oral cancer cells, in a bid to widen the application of PDT against thick and solid advanced or recurrent head and neck cancers. In vivo studies using the synthesized anti-EGFR-PEG-TiO2-UCNs following systemic administration displayed no major sub-acute or long term toxic effects in terms of blood biochemical, hematological or histopathological changes at a concentration of 50 mg/kg. NIR-PDT even in the presence of a 10 mm tissue phantom placed over the xenograft tumor, showed significant delay in tumor growth and improved survival rate compared to conventional chlorin-e6 (Ce6) PDT using 665 nm red light. Our work, one of the longest study till date in terms of safety (120 d), PDT efficacy (35 d) and survival (60 d), demonstrates the usefulness of UCN based PDT technology for targeted treatment of thick and bulky head and neck tumors.
Longitudinal analysis of antibody profiles against plakins in severe drug eruptions: emphasis on correlation with tissue damage in drug-induced hypersensitivity syndrome and drug reaction with eosinophilia and systemic symptoms
Authors: A. Takehara, Y. Aoyama, M. Kurosawa, Y. Shirafuji, H. Umemura, K. Kamiya, Y. Ushigome, Y. Kano, T. Shiohara, K. Iwatsuki
Journal: British Journal of Dermatology (2016)

The evidence for severe drug eruption as a trigger for autoimmune disease has recently increased. No information is available on how tissue damage in severe drug eruptions can induce autoimmune responses. To investigate whether the generation of autoantibodies (autoAbs) against plakin family proteins could be the cause or result of tissue damage in patients with severe drug eruptions and whether the generation of autoAbs could be prevented by systemic corticosteroids during the acute stage. We retrospectively analysed alterations of serum levels of autoAbs against plakin family proteins in patients with Stevens–Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and drug‐induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) during the acute stage and long after resolution over a period of more than 10 years. AutoAbs against plakin family proteins were detected in patients with either SJS/TEN or DiHS/DRESS regardless of the epidermal damage in the acute stage, and were sustained even long after resolution in DiHS/DRESS, indicating that those autoAbs are neither the cause nor the consequence of epidermal damage, at least in DiHS/DRESS. Severe liver damage and noncorticosteroid therapy during the early and acute stages of DiHS/DRESS were associated with the subsequent generation of these autoAbs. These autoAbs are neither necessarily the cause nor the result of epidermal damage in DiHS/DRESS, because the presence of these autoAbs was not restricted to patients with SJS/TEN but was also observed in those with DiHS/DRESS, which is characterized by lack of epidermal damage. Severe liver damage and/or immune responses that could be prevented by corticosteroids in the acute stage of DiHS/DRESS are among the causal factors contributing to the generation of autoimmune responses.
Phase II study of anlotinib for treatment of advanced medullary thyroid carcinoma.
Authors: Yongkun Sun, Yihebali Chi, Pingzhang Tang, Ming Gao, Qinghai Ji, Zhendong Li, Yuan Zhang, Zhuming Guo, Jun Wang, Xiangjing Chen
Journal: Journal of Clinical Oncology (2016)

6015 Background: Medullary thyroid carcinoma (MTC) is a rare disease with no standard therapies available in China for unresectable, advanced or relapsed MTC patients. Anlotinib is a multi-target RTK inhibitor, with inhibition activities to VEGFR1/2/3, FGFR1/2/3, PDGFRα/β, c-Kit, Ret etc in nanomole level. Recommended dose in phase I study is 12mg daily, 2 weeks on/one week off. We conducted a single-arm, multi-center phase 2 study (NCT01874873) to assess efficacy and safety of anlotinib in advanced MTC patients. Methods: Pathology-confirmed advanced or relapsed MTC patients, who cannot receive radical surgery and have measurable indicators (RECIST1.1), were treated with anlotinib. Assess efficacy every 6 weeks. The primary endpoint is PFS. This study used Simon's Two-Stage design, assuming DCR of anlotinib can achieve 70%. Results: From Sept. 2013, we recruited 58 patients in 8 centers in China, including 34 male patients and 24 female patients. Average age is 48 (22-71). One patient dropped after one cycle treatment, 2 patients without measurable lesions, 55 patients are assessable for efficacy. As of May 2015, average PFS is 12.8 months and median PFS is still not reached. 7 patients achieved PR at second treatment cycle, and 31 patients achieved PR over time (28 patients confirmed), overall ORR is 48.28% (FAS). DCR is 92.16% at week 24, and 84.53% at week 48. 58 patients are assessable for safety. Common grade III/IV AEs are: hand-foot-skin reaction (n=5), hypertension (n=3), mucositis (n=2), stomachache (n=1), diarrhea (n=1), fatigue (n=1), cholesterol increase (n=2), triglyceride increase (n=2), amylase increase (n=2), lipase increase (n=2), ALT increase (n=1), and proteinuria (n=1). 12 patients (20.7%) have dose adjustment during treatment, reducing to 10mg daily, 2 weeks on / 1 week off. Conclusions: Anlotinib has a high ORR (48.28%) for treatment of MTC, average PFS is 12.8 months and median PFS is still not reached. The disease can be controlled for long term (DCR is 92.16% at week 24). The primary endpoint of this study has been met. Meanwhile, anlotinib is well tolerated. The randomized, controlled clinical trial is ongoing. Sun Yongkun and Yihebali Chi contributed equally to this work. Clinical trial information: NCT01874873.
Epirubicin, oxaliplatin, and docetaxel (EOD) combination in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A phase II study
Authors: L. Di Lauro, L. Giacinti, M. G. Arena, S. I. Fattoruso, P. Foggi, M. Lopez
Journal: Journal of Clinical Oncology (2008)

15512 Background: The combination chemotherapy of epirubicin (E), docetaxel (D) and cisplatin showed activity in metastatic gastric cancer (Di Lauro et al, Ann Oncol 2005). We performed a phase II study substituting cisplatin with oxaliplatin (O) in chemotherapy-naive patients (pts) with gastric or GEJ adenocarcinoma. Methods: Pts with measurable distant metastases received E 50 mg/m2, O 100 mg/m2 and D 60 mg/m2 on day 1 every 3 weeks for a maximum of 8 cycles. G-CSF was used only as secondary prophylaxis. The primary endpoint was overall response rate (RR) according to RECIST. Toxicity was reported according to NCI-CTC v 3.0. Simon's two-stage design was used with 5/18 responses required in the first stage to allow continuation to 33 pts. Results: 35 pts were enrolled: M/F 20/15; median age 63 years (34–75); median ECOG PS 1 (0–2); primary tumor resected/ unresected 10/25; predominant site of disease was liver in 20 pts, nodes/peritoneum in 12 pts, lung in 2 pts and bone in 1 pt. At the time of analysis 33 pts were evaluable for response and 34 pts for toxicity. In 33 pts, 1 CR and 15 PRs were observed for an overall RR of 48.5% (95% CI, 31.5%-65.5%). Responses were obtained in 11/20 pts (55%) with liver metastases. Disease remained stable in 11 pts (33 %). Median TTP was 6.2 months (1–16+) and median OS was not reached yet. Grade 3/4 neutropenia, thrombocytopenia and anemia occurred in 53%, 3% and 9 % of the pts, respectively. Febrile neutropenia was seen in 2 pts (6%). Other grade 3 toxicities included mucositis in 2 pts (6%), vomiting in 2 pts (6%) and diarrhea in 1 pt (3%). There were no cardiac toxicity, severe neurotoxicity or treatment-related deaths. Conclusions: The EOD combination is an active and well tolerated novel chemotherapy regimen for treating metastatic gastric or GEJ adenocarcinoma and deserves further evaluation in randomized trials and in combination with molecular targeting agents. No significant financial relationships to disclose.
<i>TP53</i>Gene and Cancer Resistance in Elephants
Authors: Claudio Casola
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Plasma biomarker analysis of a phase I trial of ASA404 (vadimezan) in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer (NSCLC).
Authors: M. M. Shi, N. Funami, M. Steed, M. Motwani, D. Robinson, E. DiTomaso, J. C. Barrett, R. J. Waltzman, J. Klimovsky, K. Kobayashi
Journal: Journal of Clinical Oncology (2010)

e18035 Background: ASA404 (vadimezan, DMXAA) is a flavonoid, non-tubulin-binding tumor-vascular disrupting agent (Tumor- VDA) that causes irreversible tumor vasculature disruption and extensive hemorrhagic necrosis of the tumor core. In combination with paclitaxel and carboplatin (P/C), ASA404 increased the median overall survival of previously untreated NSCLC patients from 8.8 to 14.0 months in a phase II clinical trial. Methods: A phase I trial assessed the safety profile and tolerability of three dose levels of ASA404 (600, 1,200, and 1,800 mg/m2) administered in combination with P/C (P, 200 mg/m2; C, AUC 6) every 3 weeks in Japanese patients with NSCLC. A panel of plasma biomarkers of angiogenesis and cytokines were evaluated to investigate the pharmacodynamic effect and mechanism of action (MOA) of ASA404. Plasma VEGF and basic FGF (bFGF) were measured by multiplex assays using the Meso-Scale Discovery platform. Plasma IL-8 and macrophage chemotactic protein (MCP)1 were analyzed by Luminex beads platform. Plasma 5-hydroxyindole-3-acetic acid (5HIAA), a by-product of platelet activation and putative biomarker for ASA404's vascular disruption activity, was analyzed by tandem mass spectrometry. Results: Four-hours after ASA404 infusion at Cycle 1 Day 1, plasma 5HIAA levels increased in a dose-dependent manner by 15%, 111%, or 137% compared with pre-ASA404 treatment level in the 600 (n = 3), 1,200 (n = 6) or 1,800 (n = 6) mg/m2 groups, respectively. Plasma VEGF levels decreased by 5 to 50% after 4 h and 24 h of ASA404 infusion. Plasma bFGF levels decreased by 55 to 88% after 24 h ASA404 infusion in the three ASA404 dose groups. Furthermore, over 50% induction of plasma IL-8 and MCP-1 were observed after 24 h infusion of ASA404. Conclusions: ASA404 caused dose-dependent induction of plasma 5HIAA levels. Unlike anti-angiogenic compounds such as sunitinib, sorafenib or bevacizumab which upregulate systemic VEGF, ASA404 did not appear to cause a systemic VEGF elevation. Induction of plasma inflammatory cytokines (IL-8, MCP-1) after ASA404 treatment may represent ASA404 MOA and amplify the direct antivascular effect of ASA404. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Novartis
The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant in Mantle Cell Lymphoma
Authors: Jonathon B. Cohen, Nathan Hall, Amy S. Ruppert, Jeffrey A. Jones, Pierluigi Porcu, Robert A. Baiocchi, Sam Penza, Don M Benson, Leslie A Andritsos, Joseph M. Flynn, Steven M. Devine, Kristie A Blum
Journal: Blood (2011)
Lumen-apposing metal stents (LAMS) for pancreatic fluid collection (PFC) drainage: may not be business as usual
Authors: Ji Young Bang, Muhammad Hasan, Udayakumar Navaneethan, Robert Hawes, Shyam Varadarajulu
Journal: Gut (2016)

Lumen-apposing metal stents (LAMS) have been recently developed to improve treatment outcomes in the endoscopic management of pancreatic fluid collections (PFC), particularly in walled-off necrosis (WON), to facilitate better drainage of necrotic contents and minimise the risk of perforation and peritoneal leakage.In an ongoing randomised trial, we observed serious adverse events that included delayed bleeding, buried stent syndrome and biliary stricture that necessitated a change in the management protocol for patients with PFC treated with LAMS.
Роль статевого диморфізму у розвитку неалкогольної жирової хвороби печінки
Authors: V.B. Yahmur, N.V Nedzvetska, I.S. Kononenko
Journal: GASTROENTEROLOGY (2016)

Метаболічне ураження печінки часто супроводжує захворювання різних систем організму. Неалкогольна жирова хвороба печінки (НЖХП) — найбільш поширена патологія, що пов’язана з інсулінорезистентністю, цукровим діабетом та ожирінням. Поширеність НЖХП коливається залежно від різних факторів, серед яких — етнічне походження, вік, наявність метаболічного синдрому. Дані епідеміологічних досліджень останніх років свідчать, що жировий гепатоз майже в два рази частіше спостерігається у чоловіків порівняно з жінками дітородного віку. Відомо, що статеві гормони є важливими регуляторами обміну ліпідів і відповідають за гендерний диморфізм ліпідного профілю. У статті наведений огляд наукових досліджень щодо визначення ролі естрогенів у розвитку НЖХП на різних етапах її патогенезу: накопичення жирів, запалення та розвитку фіброзу.